Literature DB >> 17356568

Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.

Klara Felszeghy1, José Manuel Espinosa, Hélène Scarna, Anne Bérod, William Rostène, Didier Pélaprat.   

Abstract

Chronic use of psychostimulants induces enduringly increased responsiveness to a subsequent psychostimulant injection and sensitivity to drug-associated cues, contributing to drug craving and relapse. Neurotensin (NT), a neuropeptide functionally linked to dopaminergic neurons, was suggested to participate in these phenomena. We and others have reported that SR 48692, an NT receptor antagonist, given in pre- or co-treatments with cocaine or amphetamine, alters some behavioral effects of these drugs in rats. However, its efficacy when applied following repeated cocaine administration remains unknown. We, therefore, evaluated the ability of SR 48692, administered after a cocaine regimen, to interfere with the expression of locomotor sensitization and conditioned place preference (CPP) in rats. We demonstrated that the expression of locomotor sensitization, induced by four cocaine injections (15 mg/kg, i.p.) every other day and a cocaine challenge 1 week later, was attenuated by a subsequent 2-week daily administration of SR 48692 (1 mg/kg, i.p.). Furthermore, the expression of cocaine-induced CPP was suppressed by a 10-day SR 48692 treatment started after the conditioning period (four 15 mg/kg cocaine injections every other day). Taken together, our data show that a chronic SR 48692 treatment given after a cocaine regimen partly reverses the expression of locomotor sensitization and CPP in the rat, suggesting that NT participates in the maintenance of these behaviors. Our results support the hypothesis that targeting neuromodulatory systems, such as the NT systems may offer new strategies in the treatment of drug addiction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356568      PMCID: PMC2992550          DOI: 10.1038/sj.npp.1301382

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  76 in total

1.  Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: a combined in vivo electrochemical and electrophysiological study.

Authors:  F Sotty; F Soulière; P Brun; G Chouvet; R Steinberg; P Soubrié; B Renaud; M F Suaud-Chagny
Journal:  Neuroscience       Date:  1998-08       Impact factor: 3.590

2.  Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Authors:  M Yamada; M Yamada; A Lombet; P Forgez; W Rostène
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

Review 3.  A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants.

Authors:  R C Pierce; P W Kalivas
Journal:  Brain Res Brain Res Rev       Date:  1997-10

4.  Activation of neurotensin receptors in the prefrontal cortex stimulates midbrain dopamine cell firing.

Authors:  P P Rompré; S M Boye; J Moisan
Journal:  Eur J Pharmacol       Date:  1998-01-12       Impact factor: 4.432

5.  Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine.

Authors:  P P Rompré
Journal:  Eur J Pharmacol       Date:  1997-06-11       Impact factor: 4.432

Review 6.  Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions.

Authors:  W Rostene; M Azzi; H Boudin; I Lepee; F Souaze; M Mendez-Ubach; C Betancur; D Gully
Journal:  Ann N Y Acad Sci       Date:  1997-04-24       Impact factor: 5.691

7.  The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCKB receptor antagonist.

Authors:  O Valverde; C Smadja; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1997-05       Impact factor: 4.530

8.  Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade.

Authors:  V Santucci; C Gueudet; R Steinberg; G Le Fur; P Soubrié
Journal:  Synapse       Date:  1997-08       Impact factor: 2.562

9.  Direct approach for attenuating cocaine's effects on extracellular dopamine: targeting the dopamine transporter.

Authors:  A E Morgan; S P Porter; F A Clarkson; N D Volkow; J S Fowler; S L Dewey
Journal:  Synapse       Date:  1997-08       Impact factor: 2.562

10.  Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

Authors:  D Gully; B Labeeuw; R Boigegrain; F Oury-Donat; A Bachy; M Poncelet; R Steinberg; M F Suaud-Chagny; V Santucci; N Vita; F Pecceu; C Labbé-Jullié; P Kitabgi; P Soubrié; G Le Fur; J P Maffrand
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

View more
  9 in total

1.  Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine.

Authors:  F Scott Hall; Marjorie Centeno; Maria T G Perona; Jordan Adair; Paul R Dobner; George R Uhl
Journal:  Psychopharmacology (Berl)       Date:  2011-07-01       Impact factor: 4.530

Review 2.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

Review 3.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

4.  Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity.

Authors:  Darren Opland; Amy Sutton; Hillary Woodworth; Juliette Brown; Raluca Bugescu; Adriana Garcia; Lyndsay Christensen; Christopher Rhodes; Martin Myers; Gina Leinninger
Journal:  Mol Metab       Date:  2013-08-07       Impact factor: 7.422

5.  Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA.

Authors:  Kimberly A Kempadoo; Clara Tourino; Saemi L Cho; Francesco Magnani; Gina-Marie Leinninger; Garret D Stuber; Feng Zhang; Martin G Myers; Karl Deisseroth; Luis de Lecea; Antonello Bonci
Journal:  J Neurosci       Date:  2013-05-01       Impact factor: 6.167

6.  Neurotensin in the ventral pallidum increases extracellular gamma-aminobutyric acid and differentially affects cue- and cocaine-primed reinstatement.

Authors:  Mary M Torregrossa; Peter W Kalivas
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030

7.  Neurotensin agonist attenuates nicotine potentiation to cocaine sensitization.

Authors:  Paul Fredrickson; Mona Boules; Bethany Stennett; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-01-22

Review 8.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

9.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.